Vertex Pharmaceutica
VRTX
Delayed Nasdaq - 08/22 10:00:00 pm
155.48USD
+4.34%
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period December 20162017
Sales1 7012 280
EBITDA350467
Operating profit (EBIT)288484
Pre-Tax Profit (EBT)--
Net income-112182
EPS ( $ )-0,460,69
Dividend per Share ( $ )--
Yield--
Announcement Date01/25/2017
09:01pm
-
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period December 20162017
Debt--
Finance893727
Operating income (EBITDA)350467
Leverage
(Debt/EBITDA)
--
Capital Expenditure70,854,8
Book Value Per Share (BVPS)4,66 $7,43 $
Cash Flow per Share0,96 $1,98 $
Announcement Date01/25/2017
09:01pm
-
Balance Sheet Analysis
Financial Ratios
Size 2017e 2018e
Capitalization 39 199 M$ -
Entreprise Value (EV) 38 473 M$ 37 460 M$
Valuation 2017e 2018e
P/E ratio (Price / EPS) 224x 91,9x
Capitalization / Revenue 17,2x 14,6x
EV / Revenue 16,9x 14,0x
EV / EBITDA 82,3x 42,2x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 20,9x 16,7x
Profitability 2017e 2018e
Operating Margin (EBIT / Sales) 21,2% 31,6%
operating Leverage (Delta EBIT / Delta Sales) 1,99x 4,30x
Net Margin (Net Profit / Revenue) 7,98% 19,7%
ROA (Net Profit / Asset) 9,25% 11,1%
ROE (Net Profit / Equities) 25,9% 23,8%
Rate of Dividend - -
Balance Sheet Analysis 2017e 2018e
CAPEX / CA   2,40% 2,84%
Cash Flow / Sales 21,9% 33,5%
Capital Intensity (Assets / Sales) 0,86x 1,77x
Financial Leverage (Net Debt / EBITDA) -1,55x -1,96x
Price Earning Ratio
BNA & Dividende